Tags

Type your tag names separated by a space and hit enter

Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
Vaccine. 2020 05 06; 38(21):3740-3746.V

Abstract

BACKGROUND

In a randomized controlled study (NCT01622062) a 1-week, 4-site intradermal (ID, 4-4-4-0-0) post-exposure prophylaxis (PEP) rabies vaccination regimen with purified Vero cell rabies vaccine (PVRV, Verorab®, Sanofi Pasteur), either without (Group 1) or with (Group 2) purified equine rabies immunoglobulin (ERIG), patients in the Philippines achieved seroconversion rates at Day 14 that were non-inferior to that of the updated Thai Red Cross (TRC) 28-day, 2-site (2-2-2-0-2) ID regimen with ERIG (Group 3). Presented here are the annual immunogenicity data up to five years after the last primary dose, and the immunogenicity and safety data following simulated PEP with single-visit, 4-site ID regimen.

METHODS

Rabies virus neutralizing antibodies (RVNA) were determined by rapid fluorescent focus inhibition test (RFFIT). Participants (n = 397) received simulated PEP vaccination ID at Year 5 and RVNAs were assessed at Day 11 post-vaccination.

RESULTS

Seroconversion rates (RVNA titres ≥ 0.5 IU/mL) during annual follow-up remained >95% in Group 1 and were relatively stable at 80-90% in Group 2, but decreased from 80% to 64% in Group 3. RVNA geometric mean titres (GMTs) in Group 1 were consistently higher than in the other two groups, and those in Group 3 were generally lower than in the other two groups. There was a clear anamnestic response to vaccination in all groups, with all participants achieving RVNA titres ≥ 0.5 IU/mL at Day 11 post-simulated PEP booster vaccination. There were no safety concerns raised during annual follow-up and with simulated post-exposure vaccination with PVRV.

CONCLUSION

The shortened, 1-week, 4-site ID regimen with PVRV achieved persistently higher RVNA titres than the updated 2-site TRC regimen, and more participants remained seroprotected up to five years after the last dose of primary immunization. Simulated post-exposure with 4-site ID rapidly induced an anamnestic response indicative of robust protection.

Authors+Show Affiliations

Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines.Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines.Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines.Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France.Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France.Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France.Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France.Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France. Electronic address: Guy.Houillon@sanofi.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32280042

Citation

Quiambao, Beatriz P., et al. "Single-visit, 4-site Intradermal (ID) Rabies Vaccination Induces Robust Immune Responses 5 Years After 1-week, 4-site ID Primary Post-exposure Prophylaxis in the Philippines." Vaccine, vol. 38, no. 21, 2020, pp. 3740-3746.
Quiambao BP, Ambas C, Diego S, et al. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines. Vaccine. 2020;38(21):3740-3746.
Quiambao, B. P., Ambas, C., Diego, S., Bosch Castells, V., Korejwo, J., Petit, C., Rasuli, A., & Houillon, G. (2020). Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines. Vaccine, 38(21), 3740-3746. https://doi.org/10.1016/j.vaccine.2020.03.043
Quiambao BP, et al. Single-visit, 4-site Intradermal (ID) Rabies Vaccination Induces Robust Immune Responses 5 Years After 1-week, 4-site ID Primary Post-exposure Prophylaxis in the Philippines. Vaccine. 2020 05 6;38(21):3740-3746. PubMed PMID: 32280042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines. AU - Quiambao,Beatriz P, AU - Ambas,Cristina, AU - Diego,Sherylle, AU - Bosch Castells,Valérie, AU - Korejwo,Joanna, AU - Petit,Céline, AU - Rasuli,Anvar, AU - Houillon,Guy, Y1 - 2020/04/09/ PY - 2019/12/18/received PY - 2020/03/20/revised PY - 2020/03/23/accepted PY - 2020/4/14/pubmed PY - 2020/4/14/medline PY - 2020/4/14/entrez KW - Five-year follow-up KW - Intradermal regimen KW - Philippines KW - Purified Vero cell rabies vaccine KW - Rabies post-exposure prophylaxis KW - Verorab® SP - 3740 EP - 3746 JF - Vaccine JO - Vaccine VL - 38 IS - 21 N2 - BACKGROUND: In a randomized controlled study (NCT01622062) a 1-week, 4-site intradermal (ID, 4-4-4-0-0) post-exposure prophylaxis (PEP) rabies vaccination regimen with purified Vero cell rabies vaccine (PVRV, Verorab®, Sanofi Pasteur), either without (Group 1) or with (Group 2) purified equine rabies immunoglobulin (ERIG), patients in the Philippines achieved seroconversion rates at Day 14 that were non-inferior to that of the updated Thai Red Cross (TRC) 28-day, 2-site (2-2-2-0-2) ID regimen with ERIG (Group 3). Presented here are the annual immunogenicity data up to five years after the last primary dose, and the immunogenicity and safety data following simulated PEP with single-visit, 4-site ID regimen. METHODS: Rabies virus neutralizing antibodies (RVNA) were determined by rapid fluorescent focus inhibition test (RFFIT). Participants (n = 397) received simulated PEP vaccination ID at Year 5 and RVNAs were assessed at Day 11 post-vaccination. RESULTS: Seroconversion rates (RVNA titres ≥ 0.5 IU/mL) during annual follow-up remained >95% in Group 1 and were relatively stable at 80-90% in Group 2, but decreased from 80% to 64% in Group 3. RVNA geometric mean titres (GMTs) in Group 1 were consistently higher than in the other two groups, and those in Group 3 were generally lower than in the other two groups. There was a clear anamnestic response to vaccination in all groups, with all participants achieving RVNA titres ≥ 0.5 IU/mL at Day 11 post-simulated PEP booster vaccination. There were no safety concerns raised during annual follow-up and with simulated post-exposure vaccination with PVRV. CONCLUSION: The shortened, 1-week, 4-site ID regimen with PVRV achieved persistently higher RVNA titres than the updated 2-site TRC regimen, and more participants remained seroprotected up to five years after the last dose of primary immunization. Simulated post-exposure with 4-site ID rapidly induced an anamnestic response indicative of robust protection. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/32280042/Single_visit_4_site_intradermal__ID__rabies_vaccination_induces_robust_immune_responses_5_years_after_1_week_4_site_ID_primary_post_exposure_prophylaxis_in_the_Philippines_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(20)30422-9 DB - PRIME DP - Unbound Medicine ER -